Component
Objective response in colorectal cancer
Independent measured endpoint or substance; model, assay and exposure are retained in each linked finding.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
No objective improvement occurred among the vitamin C trial participants with measurable disease.
Experimental context and source evidence
- experimental_model
- Double-blind randomized trial: 100 advanced colorectal cancer patients without previous cytotoxic chemotherapy.
- exposure
- Oral vitamin C 10 g/day versus placebo. The 1985 abstract does not specify route; route is cross-checked in Chen2005 Introduction, which identifies the two oral randomized trials through references 5 and 6.
- limitations
- Abstract does not provide the subgroup denominator; no extrapolation to every cancer or pharmacological regimen.
- nutrient_topic
- Vitamin C research collection; topical membership is not evidence of a direct dietary effect. · Vitamin C
- organism
- Homo sapiens
- plain_language
- The trial did not report a measurable tumor response in that subgroup.
- primary_references
- [c-moertel1985] High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison (1985). https://pubmed.ncbi.nlm.nih.gov/3880867/ DOI: 10.1056/nejm198501173120301
- route_provenance
- Oral route cross-checked in Chen2005 Introduction and reference 6 (Moertel1985): https://pmc.ncbi.nlm.nih.gov/articles/PMC1224653/ . Clinical outcomes come from the Moertel abstract.
- tissue_or_cell_type
- Human blood or whole-person endpoints
Vitamin C: mechanisms, deficiency and nutrient interactions (2026-09-17) · lines 1793–1804
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Double-blind randomized trial: 100 advanced colorectal cancer patients without previous cytotoxic chemotherapy. · source_derived_draft · unverified_draft
### c-oral-colorectal-objective-response-null No objective improvement occurred among the vitamin C trial participants with measurable disease. Condition category: normal nutrient_topic: Vitamin C research collection; topical membership is not evidence of a direct dietary effect. plain_language: The trial did not report a measurable tumor response in that subgroup. organism: Homo sapiens tissue_or_cell_type: Human blood or whole-person endpoints experimental_model: Double-blind randomized trial: 100 advanced colorectal cancer patients without previous cytotoxic chemotherapy. limitations: Abstract does not provide the subgroup denominator; no extrapolation to every cancer or pharmacological regimen. exposure: Oral vitamin C 10 g/day versus placebo. The 1985 abstract does not specify route; route is cross-checked in Chen2005 Introduction, which identifies the two oral randomized trials through references 5 and 6. route_provenance: Oral route cross-checked in Chen2005 Introduction and reference 6 (Moertel1985): https://pmc.ncbi.nlm.nih.gov/articles/PMC1224653/ . Clinical outcomes come from the Moertel abstract. [c-moertel1985] High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison (1985). https://pubmed.ncbi.nlm.nih.gov/3880867/ DOI: 10.1056/nejm198501173120301
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.